Nature: LongeVC Portfolio Company Trogenix Publishes Breakthrough Pre-Clinical Data

Our portfolio company Trogenix has announced the publication of landmark pre-clinical data in Nature, demonstrating complete tumor eradication and durable protection in an aggressive brain cancer model that closely mimics human glioblastoma (GBM).

In the study, a single dose of Trogenix's proprietary Synthetic Super-Enhancers (SSEs) achieved complete tumor clearance in 83% of treated cases, with no recurrence and no toxicity over 11 months. The dual-payload approach combines direct tumor killing with immune activation, effectively functioning as an in-situ vaccine that generates lasting immunological memory against cancer recurrence.

Trogenix is now preparing to dose its first patients in a Phase I/II clinical trial for glioblastoma, expected to begin in Q2 2026.

Read the full paper in Nature here and the press release here.